

Full-Year 2025 *Results*



- 2025 marked another strong year of profitable growth for Sanofi as we delivered multiple regulatory approvals, advanced our pipeline with several positive Phase 3 readouts, and achieved three successful launches across medicines and vaccines. This momentum reflects our evolution as an R&D-driven, AI-powered biopharma company harnessing the power of science to deliver breakthroughs for patients. •

Paul Hudson
Chief Executive Officer, Sanofi

Full-Year 2025 company sales

€43.6bn

+9.9% at constant exchange rates
+6.2% on a reported basis

Full-Year 2025 business earnings per share

€7.83

+15.0% at constant exchange rates
+10.0% on a reported basis

Sales by category



Dupixent

€15.7bn



Pharma launches

€3.9bn



Vaccines

€7.9bn



Other medicines

€16.1bn

sanofi

Full-Year 2025 *Results*

Sales by geography

US	Europe	Rest of the World
€22.2bn	€9.2bn	€12.3bn

Pipeline progress in Q4 2025

- **10** regulatory approvals across immunology and rare diseases
- **7** phase 3 study starts
- **4** regulatory submission acceptances in the US, Europe and Japan

For further information on Full-Year 2025 results and definitions of financial indicators, please refer to the press release issued on January 29, 2026 at: www.sanofi.com/en/investors